USSTOCK.TODAY
Pre-Market
Log in Sign up

Major Stock Price Fluctuations Following Analyst Rating Adjustments

Investing.com · ·by G4L

DOX
DOX Amdocs Ltd
$41.74 -0.83%
View chart & analysis →
INO INO +24.28%
  1. 1Inovio Pharmaceuticals (INO) shares rose +213.7% following FDA approval of its first product, INO-3107 (Boseuric).
  2. 2Ibotta (IBTA) shares rose +20.5% alongside third-quarter results as Goldman Sachs upgraded its rating from Buy to Neutral.
  3. 3Amdocs (DOX) shares fell -30.1% after Oppenheimer lowered its rating.

So what's the key point?

Inovio Pharmaceuticals shares rose 213.7% on news of product approval. Ibotta rose due to changes in expert ratings, and Amdocs fell as its rating was lowered.

Source Investing.com · View original ↗

Related 3-line summaries

Inovio Pharmaceuticals shares drop 25% following announcement of $75 million public offering Investing.com · 2d agoAmdocs Q4 revenue up approximately 3.8% and FY2027 outlook lowered The Motley Fool +1 · 5d agoAmdocs Limited Reports $4.7 Billion in FY2026 Revenue and Announces Business Expansion Nasdaq +3 · 6d ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news